Overview

Location [1]
1p34.2
Pathway
Immune checkpoints
Protein [2]
Thrombopoietin receptor
Synonyms [1]
C-MPL, MPLV, THCYT2, TPOR, CD110

MPL proto-oncogene, thrombopoietin receptor (MPL) is a gene that encodes a protein that resembles members of the hematopoietic receptor superfamily. Missense, nonsense, and silent mutations are observed in cancers such as colorectal cancer, leukemias, lung cancer, and skin cancer.

MPL is altered in 1.24% of all cancers with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].

MPL GENIE Cases - Top Diseases

The most common alterations in MPL are MPL Mutation (1.04%), MPL Amplification (0.20%), MPL Exon 10 Mutation (0.13%), MPL W515L (0.19%), and MPL Loss (0.04%) [3].

MPL GENIE Cases - Top Alterations

Significance of MPL in Diseases

Myelofibrosis +

Myeloid Neoplasm +

Acute Myeloid Leukemia +

Multiple Myeloma +

Myelodysplastic Syndrome With Excess Blasts-2 +

Plasma Cell Leukemia +

Secondary Acute Myeloid Leukemia +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.